MONTREAL, November 27, 2023 — The Research Institute at McGill University Health Center (RI-MUHC) will host a new phase 3 randomized clinical trial. TROPION-Breast 04as McPeak Sirois Group announced today., a provincial consortium of cancer centers across Quebec focused on breast cancer research. The trial is aimed at patients with previously untreated triple-negative breast cancer (TNBC) or hormone receptor (HR)-low/HER2-negative early breast cancer. This study evaluates the safety and efficacy of neoadjuvant datopotamab deruxtecan (or Dato-DXd) in combination with durvalumab, followed by adjuvant durvalumab with or without chemotherapy, compared to the existing standard of care for TNBC. To do. We are proud to report that the world’s first patients enrolled in this pivotal trial are from the Cedars Cancer Center at McGill University Health Center (MUHC).
TNBC has a high recurrence rate and a high probability of metastasis. It is resistant to conventional treatments, leading to poor prognosis and survival outcomes. TNBC tends to be more common in women under 40. Her TROPION-Breast04 clinical trial is expected to have the potential to improve the lives of eligible patients in this setting, as new and more effective treatment approaches are needed.
The study is being led locally by Dr. Jamil Acela, a medical oncologist at MUHC, researcher in the RI-MUHC Cancer Research Program, and chair of the academic committee. McPeak Sirois Group. Dr. Acela is also a member of the study’s global steering committee.
“Soon, in Quebec, Canada, and many other countries, patients diagnosed with triple-negative or HR-low/HER2-negative breast cancer will have a unique opportunity to participate in Phase 3 trials exploring innovative drugs. This study provides: “This is, in my opinion, a unique opportunity to increase the chances of recovery, reduce the risk of relapse and improve quality of life. I strongly encourage all patients considering neoadjuvant chemotherapy to discuss this opportunity with their oncologist,” says Dr. Acela.
For more information:
read Press release on website.
watch video We share our treatment experience with Nancy Brunette, a MUHC patient who received Dato-DXd in combination with durvalumab as adjuvant therapy in a previous study.
If you are interested in participating in a clinical trial, please contact us. [email protected]
Media inquiries
Fabienne Landry
Communication coordinator, research
McGill University Health Center
[email protected]
Mobile: 514 812-7722
